Citadel Advisors’s Nasus Pharma NSRX Stock Holding History

Citadel Advisors’s Portfolio NSRX Stock Details NSRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$77K	Buy	+22,004	New	+$64.5K	﹤0.01%	12868

Other funds holding NSRX

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

Citadel Advisors's NSRX Position: Q2 2026 in Review

Citadel Advisors opened a new position in Nasus Pharma (NSRX) in Q2 2026: 22,004 shares worth $77K. The stake represents ﹤0.01% of the portfolio and ranks #12868 among its holdings.

10 funds tracked by Wall St. Rank hold NSRX as of Q2 2026.

Citadel Advisors held 22,004 shares of Nasus Pharma worth $77K as of Q2 2026.
Nasus Pharma was a new Citadel Advisors position in Q2 2026.
Nasus Pharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12868 holding.
10 funds tracked by Wall St. Rank held Nasus Pharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.